View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Fathom Holdings Prices Underwritten Public Offering of Common Stock

Fathom Holdings Prices Underwritten Public Offering of Common Stock CARY, N.C., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. After the underwriting dis...

 PRESS RELEASE

Fathom Holdings Announces Proposed Offering of Common Stock

Fathom Holdings Announces Proposed Offering of Common Stock CARY, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform, today announced a proposed primary offering of its common stock in an underwritten public offering. The Company also expects to grant to the underwriters of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 2, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in conne...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 3, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

PennantPark Investment Corporation Announces Monthly Distribution of $...

PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT), as previously announced on July 14, 2025, declared its monthly distribution for September 2025 of $0.08 per share, payable on September 30, 2025 to stockholders of record as of September 15, 2025. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distributions will be reported to stockholders on Form 1099 after the end of the cal...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Westlake Chemical Partners Lp: 1 director

A director at Westlake Chemical Partners Lp bought 7,462 shares at 21.877USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

 PRESS RELEASE

Fathom to Present at the 2025 Gateway Conference on September 4th

Fathom to Present at the 2025 Gateway Conference on September 4th CARY, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Fathom Holdings Inc. (Nasdaq: FTHM) (“Fathom” or the “Company”), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings for brokerages and agents, will participate in the , which is being held September 3-4, at the Four Seasons Hotel in San Francisco, CA. Fathom CEO Marco Fregenal is scheduled to present on Thursday, September 4, at 10:00 am Pacific Time (PT). The presentation will be webcas...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Agree Realty Corp: 1 director

A director at Agree Realty Corp bought 4,850 shares at 72.150USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results an...

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2...

 PRESS RELEASE

PennantPark Investment Corporation Announces Financial Results for the...

PennantPark Investment Corporation Announces Financial Results for the Quarter Ended June 30, 2025 MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) announced today its financial results for the third quarter ended June 30, 2025. HIGHLIGHTS      Quarter ended June 30, 2025 (unaudited)($ in millions, except per share amounts)                             Assets and Liabilities:     Investment portfolio (1)   $1,171.6 Net assets   $480.6 Net asset value per share   $7.36 Quarterly change in net asset value per share    (1.6)%      Credit Facility   $31...

 PRESS RELEASE

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results...

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, ...

 PRESS RELEASE

PennantPark Investment Corporation Announces Monthly Distributions of ...

PennantPark Investment Corporation Announces Monthly Distributions of $0.08 per Share MIAMI, Aug. 04, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT), as previously announced on July 14, 2025, declared its monthly distribution for August 2025 of $0.08 per share, payable on September 2, 2025 to stockholders of record as of August 15, 2025 and declared its monthly distribution for September 2025 of $0.08 per share, payable on September 30, 2025 to stockholders of record as of September 15, 2025. The distributions are expected to be paid from taxable ...

 PRESS RELEASE

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employm...

 PRESS RELEASE

PennantPark Investment Corporation’s Unconsolidated Joint Venture, Pen...

PennantPark Investment Corporation’s Unconsolidated Joint Venture, PennantPark Senior Loan Fund, LLC Completes the Partial Refinancing of its $300 Million Securitization, Lowering the Cost of Financing MIAMI, July 23, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the “Company”) (NYSE: PNNT) today announced that PennantPark Senior Loan Fund, LLC (“PSLF”) through PSLF’s wholly-owned and consolidated subsidiary, PennantPark CLO VII, LLC (“CLO VII”) has closed the partial refinancing of its $300 million debt securitization. The partial refinancing of this securitization (the ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch